" class="no-js "lang="en-US"> Eisai Archives - Medtech Alert
Monday, November 11, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease

BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain

Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]

Health Canada Accepts New Drug Submission for lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB’s partner Eisai announced today that Health Canada has accepted a New Drug Submission […]

Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701

Eisai announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical […]

U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI™ (lecanemab-irmb) for Veterans Living with Early Stages of Alzheimer's Disease

BioArctic AB’s partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing […]

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

Eisai and Biogen announced today that the Biologics License Application (BLA) for lecanemab, an investigational […]

BioArctic: Lecanemab Receives Priority Review Status in Japan

BioArctic AB’s partner Eisai has announced that the application for manufacturing and marketing approval for […]

European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease

BioArctic AB‘s partner Eisai have announced that the European Medicines Agency (EMA) has accepted a […]

Eisai Submits Marketing Application for lecanemab for Alzheimer's

BioArctic AB’s partner Eisai announced today that Eisai has submitted a marketing authorization application for […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more